Bernstein lowered the firm’s price target on Agilent (A) to $125 from $145 and keeps a Market Perform rating on the shares. With tariffs, concerns about NIH and broader academic/government funding, and HHS hits to pharma that have already come and that may still be in the works, the firm believes the recovery in tools isn’t happening the way it hoped it would at the beginning of the year. Measures of the health sector show that these theoretical risks are actually playing out in the numbers, and Bernstein heads into Q1 cautious.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent price target lowered to $128 from $156 at BofA
- Agilent price target lowered to $115 from $138 at Barclays
- Agilent placed on ‘positive catalyst watch’ at Citi
- Agilent, Seagate, Dollar Tree, Coupang, Appian: Insider Moves Unveiled
- Agilent xCELLigence RTCA instrumentation applied in recent FDA approval